Phathom Pharmaceuticals reports over 790,000 total VOQUEZNA® prescriptions filled to date, with a 28% increase in filled prescriptions from Q2 2025. Net revenues reached $49.5 million, up 25% quarter over quarter, with cash operating expenses down 43%. Full-year 2025 revenue guidance updated to $170–$175 million, with expectations of achieving operating profitability in 2026. Management will host a conference call today at 8:00 a.m. ET.

Recent business highlights include the initiation of a Phase 2 trial for VOQUEZNA in Eosinophilic Esophagitis, data from a Phase 3 trial showing improvement in nocturnal GERD symptoms, and the addition of key leadership members to the team. Phathom expects New Chemical Entity (NCE) exclusivity for VOQUEZNA through May 2032, with entry of a generic drug unlikely before 2033.

Financially, net revenues for the third quarter of 2025 were $49.5 million, with research and development expenses at $7.0 million and selling, general, and administrative expenses at $51.6 million. Operating expenses were $58.6 million, with a net loss of $30.0 million. Cash and cash equivalents as of September 30, 2025, were $135.2 million, with net cash usage improving by 77% from the second quarter. Full-year 2025 revenue guidance has been updated to $170-$175 million.

Phathom Pharmaceuticals will host a conference call today at 8:00 a.m. EDT to discuss its third quarter 2025 financial results and business highlights. Non-GAAP financial measures have been provided, including adjusted operating expenses, net loss, and adjusted net loss per share, to offer investors a more meaningful understanding of ongoing operating performance. Phathom Pharmaceuticals focuses on the development and commercialization of novel treatments for gastrointestinal diseases, with in-licensed rights to vonoprazan marketed as VOQUEZNA tablets for various GI conditions.

Read more at GlobeNewswire: Phathom Pharmaceuticals Reports Third Quarter 2025